Sopharma AD-Sofia's Total Assets for the quarter that ended in Mar. 2026 was zł4,649 Mil.
During the past 12 months, Sopharma AD-Sofia's average Total Assets Growth Rate was 8.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 17.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 8.50% per year.
During the past 13 years, Sopharma AD-Sofia's highest 3-Year average Total Assets Growth Rate was 17.80%. The lowest was 2.30%. And the median was 6.65%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sopharma AD-Sofia's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sopharma AD-Sofia Total Assets Related Terms
Sopharma AD-Sofia Total Assets Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sopharma AD-Sofia's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a Total Assets of zł4,649 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Total Assets too high?
Sopharma AD-Sofia's current Total Assets is zł4,649 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Total Assets compare to MCK and CAH?
Sopharma AD-Sofia's Total Assets of zł4,649 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Distribution company?
A good Total Assets depends on the Medical Distribution industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Total Assets is zł4,649 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł12.63, compared to a current price of zł7.70 — trading 39% below its estimated fair value. The current Total Assets is zł4,649 Mil. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Total Assets is zł4,649 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.70 is trading 39% below its estimated GF Value™ of zł12.63.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Total Assets: zł4,649 Mil
GF Value™: zł12.63 vs. price of zł7.70 (39% below fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score
Get the complete analysis for WAR:SPH
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
